Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury
Joint Authors
Wan, Limei
Wu, Weibin
Jiang, Shunjun
Wan, Shanhe
Meng, Dongmei
Wang, Zhipeng
Zhang, Jiajie
Wei, Li
Yu, Pengjiu
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-11-10
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Recent studies have illuminated that blocking Ca2+ influx into effector cells is an attractive therapeutic strategy for lung injury.
We hypothesize that T-type calcium channel may be a potential therapeutic target for acute lung injury (ALI).
In this study, the pharmacological activity of mibefradil (a classical T-type calcium channel inhibitor) was assessed in a mouse model of lipopolysaccharide- (LPS-) induced ALI.
In LPS challenged mice, mibefradil (20 and 40 mg/kg) dramatically decreased the total cell number, as well as the productions of TNF-α and IL-6 in bronchoalveolar lavage fluid (BALF).
Mibefradil also suppressed total protein concentration in BALF, attenuated Evans blue extravasation, MPO activity, and NF-κB activation in lung tissue.
Furthermore, flunarizine, a widely prescripted antimigraine agent with potent inhibition on T-type channel, was also found to protect mice against lung injury.
These data demonstrated that T-type calcium channel inhibitors may be beneficial for treating acute lung injury.
The important role of T-type calcium channel in the acute lung injury is encouraged to be further investigated.
American Psychological Association (APA)
Wan, Limei& Wu, Weibin& Jiang, Shunjun& Wan, Shanhe& Meng, Dongmei& Wang, Zhipeng…[et al.]. 2020. Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury. Mediators of Inflammation،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1191697
Modern Language Association (MLA)
Wan, Limei…[et al.]. Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury. Mediators of Inflammation No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1191697
American Medical Association (AMA)
Wan, Limei& Wu, Weibin& Jiang, Shunjun& Wan, Shanhe& Meng, Dongmei& Wang, Zhipeng…[et al.]. Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury. Mediators of Inflammation. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1191697
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191697